본문바로가기

central nervous system

메인페이지로 이동
Business
Life Science
ETC
혈액순환개선제
Suvexx Tab.
Category
ETC
Indication(s)·Usage
  • Suvexx® is indicated for the acute treatment of migraine with or without aura in adults (≥18 years of age).
Effective components
85mg Sumatriptan (as sumatriptan succinate) / 500 mg Naproxen sodium

Active ingredient(s) and Contents

  • Effective components

    • 85mg Sumatriptan (as sumatriptan succinate) / 500 mg Naproxen sodium

  • Other

    • croscarmellose sodium, dibasic calcium phosphate, magnesium stearate, microcrystalline cellulose, povidone, sodium bicarbonate, talc, Opadry blue (03K205000)

Dosage and administration

  • Suvexx® may be administered with or without food. Tablets should not be split, crushed, or chewed. Suvexx® is not indicated for the prophylactic therapy of migraine attacks.

    ○ Dosage in Adults
    The recommended dosage for adults is 1 tablet of Suvexx® 85/500 mg. Suvexx® 85/500 mg contains a dose of sumatriptan higher than the lowest effective dose. The choice of the dose of sumatriptan, and of the use of a fixed combination such as in Suvexx® 85/500 mg should be made on an individual basis, weighing the possible benefit of a higher dose of sumatriptan with the potential for a greater risk of adverse reactions. The maximum recommended dosage in a 24-hour period is 2 tablets, taken at least 2 hours apart. The safety of treating an average of more than 5 migraine headaches in adults in a 30-day period has not been established. Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals.

    ○ Dosing in Patients with Renal Impairment
    Suvexx® should be avoided in patients with renal failure and those with severe renal impairment (creatinine clearance <30 mL/min). Suvexx® is not recommended in patients with mild (creatinine clearance: 60-89 mL/min) or moderate (creatinine clearance: 30-59 mL/min) renal impairment.

    ○ Dosing in Patients with Hepatic Impairment
    Suvexx® should be avoided in patients with moderate and severe (Child Pugh B and C) hepatic impairment. Suvexx® is not recommended in patients with mild hepatic impairment (Child Pugh A).

Storage and handling

  • Store at 1~30°C